US equities |
NVDA $238.92 ▲+2.12% SPCX $168.07 ▲+5.73% MU $1,060.49 ▼-1.34% TSLA $380.48 ▲+2.67% MSFT $527.15 ▲+1.86% SNDK $1,692.17 ▼-1.62% INTC $116.68 ▼-2.22% META $742.83 ▲+2.03%
FinancialContent

Articles published by Tevogen Bio Inc

< Previous 1 2 3 4 5 Next >
News headline image
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
News headline image
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
News headline image
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
News headline image
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
News headline image
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
News headline image
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio Announces 2025 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
News headline image
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
< Previous 1 2 3 4 5 Next >